Benzinga | Mar 10, 2021 04:37PM EST

Zentalis Pharma Reports Will Present Late-Breaker Oral Presentation At American Association For Cancer Research Apr. 10

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that three abstracts have been accepted for presentation, including a late-breaker on its WEE1 inhibitor, ZN-c3, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021. The meeting will be held virtually on April 10-15 and May 17-21, 2021.

"The important data we are presenting at AACR supports the ability of our Integrated Discovery Engine to develop differentiated oncology therapeutic candidates across diverse cancer targets and types," commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis Pharmaceuticals. "We especially look forward to presenting clinical data from our ongoing Phase 1 monotherapy trial of our WEE1 inhibitor, ZN-c3, selected for a late-breaking session. In addition, results from two cell-based studies of ZN-c3, and our EGFR inhibitor, ZN-e4, demonstrated impressive selectivity and tolerability, which we believe positions these candidates to improve upon the constraints of existing products."

Late-Breaker Oral Presentation

Title Clinical activity of a single-agent ZN-c3, an oral WEE1 inhibitor, in a Phase 1 dose-escalation trial in patients with advanced solid tumors

Session: Early Clinical Trials with New Anticancer Agents

Presentation Number: CT016

Date/Time: Saturday, April 10, 2021 at 1:30 p.m. EDT

Poster Presentations

Title Discovery of ZN-c3, a potent Wee-1 inhibitor with a differentiated pharmacologic and kinase selectivity profile

Session: Molecular and Cellular Biology / Genetics

Abstract ID: 1965

Date/Time: Available starting on Saturday, April 10, 2021 at 8:30 a.m. EDT

Title: Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer

Session: Oncogene Growth Factors and their Receptors

Abstract ID: 2423

Date/Time: Available starting on Saturday, April 10, 2021 at 8:30 a.m. EDT